# A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

> **NCT05798819** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Guangzhou Gloria Biosciences Co., Ltd.** · enrollment: 424 (estimated)

## Conditions studied

- Persistent, Recurrent, or Metastatic Cervical Cancer

## Interventions

- **DRUG:** GLS-010
- **DRUG:** Placebo
- **DRUG:** paclitaxel
- **DRUG:** cisplatin
- **DRUG:** carboplatin
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT05798819
- **Lead sponsor:** Guangzhou Gloria Biosciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-05-01
- **Primary completion:** 2025-05-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 424 (ESTIMATED)
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05798819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05798819, "A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05798819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*